2020
Incidence and determinants of QT interval prolongation in COVID‐19 patients treated with hydroxychloroquine and azithromycin
Maraj I, Hummel JP, Taoutel R, Chamoun R, Workman V, Li C, Tran L, DelVecchio A, Howes C, Akar JG. Incidence and determinants of QT interval prolongation in COVID‐19 patients treated with hydroxychloroquine and azithromycin. Journal Of Cardiovascular Electrophysiology 2020, 31: 1904-1907. PMID: 32485061, PMCID: PMC7300464, DOI: 10.1111/jce.14594.Peer-Reviewed Original Research
2018
Periprocedural Use of Oral Anticoagulation Therapy in Patients Undergoing Atrial Fibrillation Ablation
Maraj I, Gonzalez MD, Naccarelli GV. Periprocedural Use of Oral Anticoagulation Therapy in Patients Undergoing Atrial Fibrillation Ablation. Journal Of Innovations In Cardiac Rhythm Management 2018, 9: 3274-3281. PMID: 32477818, PMCID: PMC7252752, DOI: 10.19102/icrm.2018.090801.Peer-Reviewed Original ResearchAtrial fibrillationStroke preventionCatheter ablationLeft atrial appendage occlusion devicesAtrial appendage occlusion devicesRhythm control strategyOral anticoagulation therapyImportant treatment strategyRisk of strokeAtrial fibrillation ablationCommon sustained arrhythmiaLeft atrial appendageClinical practice todayOral anticoagulationPeriprocedural useAnticoagulation therapySurgical exclusionFibrillation ablationSustained arrhythmiaDrug optionsAtrial appendageTreatment strategiesHigh riskOcclusion devicePatients
2017
Long-term outcomes of different ablation strategies for ventricular tachycardia in patients with structural heart disease: systematic review and meta-analysis
Briceño DF, Romero J, Villablanca PA, Londoño A, Diaz JC, Maraj I, Batul SA, Madan N, Patel J, Jagannath A, Mohanty S, Mohanty P, Gianni C, Della Rocca D, Sabri A, Kim SG, Natale A, Di Biase L. Long-term outcomes of different ablation strategies for ventricular tachycardia in patients with structural heart disease: systematic review and meta-analysis. EP Europace 2017, 20: 104-115. PMID: 28575378, DOI: 10.1093/europace/eux109.Peer-Reviewed Original ResearchConceptsStructural heart diseaseStable ventricular tachycardiaLong-term outcomesVA recurrenceVentricular tachycardiaCause mortalityStandard ablationHeart diseaseExtensive substrate modificationVentricular arrhythmia recurrenceComposite primary outcomeDifferent ablation strategiesIschemic substrateArrhythmia recurrenceIschemic cardiomyopathyPrimary outcomeMAIN OUTCOMESubstrate modificationAblation strategyLower riskElectronic searchPatientsRecurrenceSystematic reviewMortality
2015
Use of vascular closure device is safe and effective in electrophysiological procedures
Maraj I, Budzikowski AS, Ali W, Mitre CA, Kassotis J. Use of vascular closure device is safe and effective in electrophysiological procedures. Journal Of Interventional Cardiac Electrophysiology 2015, 43: 193-195. PMID: 25921347, DOI: 10.1007/s10840-015-0005-5.Peer-Reviewed Original ResearchConceptsVascular closure deviceClosure deviceElectrophysiological proceduresAccess siteCollagen plug-based vascular closure deviceResultsIn 26 patientsRetrospective chart reviewVascular access sitePeriprocedural anticoagulationChart reviewVenous accessFemoral veinFemoral arteryRetrospective analysisArterial closurePatientsMean numberVeinAnticoagulationEcchymosisComplicationsArteryPurposeLittleGroinVisits